Roughly 10% of fecal immunochemical tests (FIT) used for colorectal cancer (CRC) screening by a safety-net health system contained unsatisfactory samples that could not be processed. And fewer than ...
Please provide your email address to receive an email when new articles are posted on . In a prospective study, researchers enrolled 457 asymptomatic participants (mean age 61.4 years; 75% women) from ...
Fecal immunochemical testing and fecal calprotectin effectively predict mucosal healing in patients with ulcerative colitis, although a fecal immunochemical test appears to have superior sensitivity ...
Commercial FITs can match NG-MSDT diagnostic results for CRC by lowering the positivity threshold, enhancing sensitivity while maintaining specificity. FITs are accessible, noninvasive CRC screening ...
Hosted on MSN
Multitarget stool DNA tests cost more than FIT for early colorectal cancer detection, study finds
A brief research report compared screening costs per early-detected colorectal cancer (CRC) case among fecal immunochemical tests (FIT), multitarget stool DNA tests (MSDT) and next-generation MSDTs (N ...
Wilmington, Delaware, United States, June 06, 2023 (GLOBE NEWSWIRE) -- The market value of fecal immunochemical diagnostic tests (FITs) is expected to reach US$ 2.1 billion by 2031. Between 2023 and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback